Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
872
datasets available to search
ShareScore release 0.9.0
Dataset results
872 results for “disease progression”
Dynamic epi-transcriptomic landscape mapping with disease progression in ER-positive breast cancer
GEO Series GSE176535. Homo sapiens. 31 samples. Type: Expression profiling by high throughput sequencing; Methylation profiling by high throughput sequencing.
Indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand, mediates progressive glomerular disease by damaging podocytes
GEO Series GSE51834. Homo sapiens. 6 samples. Type: Expression profiling by array.
Broad rim lesions are a novel pathological / morphological and imaging biomarker for rapid disease progression in Multiple Sclerosis (part 2)
GEO Series GSE281805. Homo sapiens. 232 samples. Type: Other.
Epigenomics Studies in Acute Myeloid Leukemia disease progression [enhanced RRBS-seq]
GEO Series GSE83532. Homo sapiens. 293 samples. Type: Methylation profiling by high throughput sequencing.
Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis
GEO Series GSE4271. Homo sapiens. 200 samples. Type: Expression profiling by array.
Expression patterns throughout disease progression and impact on neuroAIDS.
GEO Series GSE2393. Macaca mulatta; Homo sapiens. 34 samples. Type: Expression profiling by array.
microRNA Profile in Stage I Clear Cell Renal Cell Carcinoma Predicts Progression to Metastatic Disease
GEO Series GSE131961. Homo sapiens; synthetic construct. 73 samples. Type: Expression profiling by RT-PCR.
Dataset for the project "Corticocortical signal transmission and brain connectivity alterations at prodromal stage and during the progression of Alzheimer's disease: A multimodal approach of TMS-EEG and advanced MRI" (GR-2016-02364132)
<p><strong>Aim 1:</strong></p> <p><u>Validation of STT as measure of WM integrity and as diagnostic marker of AD</u>. The first step to test the potential of the STT as AD marker is to establish if the SST can differentiate between patients (LOAD, aMCI) and healthy individuals and its relationship with clinical symptoms and with well-established measures of connectivity.</p> <p> <strong>Aim 2:</strong></p> <p><u>Connectivity changes, evaluated as in aim 1, as prognostic marker of disease progression</u>. Another crucial point is to establish if STT can capture brain connectivity alterations with disease progression, if they parallel WM integrity alterations and cognitive decline. Moreover, the potential contribution of STT as prognostic marker can be established by investigating which measure, or combination of measures, of brain connectivity at the baseline best predicts the conversion to AD in aMCI cases.</p> <p> <strong>Aim3:</strong></p> <p><u>Connectivity changes in EOAD patients.</u> The comparison of connectivity alterations between EOAD and LOAD at the baseline and during the disease progression will be a crucial step to establish the efficacy of STT as a marker of differential diagnosis in atypical forms of AD.</p> <p> </p> <p><strong>The present dataset contains the following files and folders:</strong></p> <p> </p> <p>File: <strong>Demographics_allparticipants.xlsx</strong> contains demographic and clinical data of the entire sample</p> <p>File: <strong>Hippocampal volume.xlsx</strong> data used to extract hippocampal atrophy as AD biomarker</p> <p> </p> <p>Folder: <strong>Aim1</strong></p> <p>- <strong>READ ME</strong> AIM1.txt explains folder structure</p> <p>- <strong>TMS-EEG</strong> data of HC, MCI and LOAD at T0 are organized in 3 files with TMS-Evoked Potentials (.mat format). The resting motor threshold (rMT) measured to set TMS intensity (.xlsx file)</p> <p>- <strong>Neuropsychological</strong> data of HC, MCI and LOAD at T0 (.xlsx format)</p> <p>- <strong>fMRI</strong> folder contains coordinates of the hotspot for the stimulated functional networks of HC, MCI and LOAD at T0</p> <p>- <strong>DTI</strong> data (.xlsx format) reports microstructural integrity data for major inter-hemispheric and intra-hemispheric tracts of HC, MCI and LOAD at T0</p> <p> </p> <p>- Folder: <strong>Aim2</strong></p> <p>- <strong>READ ME</strong> AIM2.txt explains folder structure</p> <p>- <strong>TMS-EEG</strong> data are organized in one file that includes TMS-Evoked Potentials of HC, MCI and LOAD at T0 and T1 (.mat format). The resting motor threshold (rMT) measured to set TMS intensity (.xlsx file)</p> <p>- <strong>Neuropsychological</strong> data of HC, MCI and LOAD at T1 (.xlsx format)</p> <p>- <strong>fMRI</strong> folder contains coordinates of the hotspot for the stimulated functional networks of HC, MCI and LOAD at T1</p> <p>- <strong>DTI</strong> data (.xlsx format) reports microstructural integrity data for major inter-hemispheric and intra-hemispheric tracts of HC, MCI and LOAD at T0 and T1</p> <p> </p> <p>Folder: <strong>Aim3</strong></p> <p> <strong>READ ME</strong> AIM2.txt explains folder structure</p> <p>- <strong>TMS-EEG</strong> data are organized in two files that includes TMS-Evoked Potentials of EOAD and LOAD at T0 and T1 (.mat format). The resting motor threshold (rMT) measured to set TMS intensity (.xlsx file)</p> <p>- <strong>Neuropsychological</strong> data of EOAD and LOAD at T0 and T1 (.xlsx format)</p> <p>- <strong>fMRI</strong> folder contains coordinates of the hotspot for the stimulated functional networks of EOAD and LOAD at T0 and T1</p> <p>- <strong>DTI</strong> data (.xlsx format) reports microstructural integrity data for major inter-hemispheric and intra-hemispheric tracts of EOAD and LOAD at T0 and T1</p> <p> </p> <p>Restricted Access Conditions: Users must clarify how they intend to use data here uploaded and whether the research protocol has been approved by an Ethics committee. Data on unpublished results will be available, under the same restrictions, after publication.</p>
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression
ClinicalTrials.gov study NCT06084923. IPD Sharing: NO. Countries: 0. Publications: 0.
The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters
ClinicalTrials.gov study NCT04824222. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression
ClinicalTrials.gov study NCT04880369. IPD Sharing: YES. Countries: 0. Publications: 0.
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lympho
ClinicalTrials.gov study NCT06839872. IPD Sharing: YES. Countries: 0. Publications: 0.
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
ClinicalTrials.gov study NCT00002166. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
ClinicalTrials.gov study NCT01500499. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study
ClinicalTrials.gov study NCT03394521. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Disease Progression in ms
ClinicalTrials.gov study NCT07292116. IPD Sharing: NO. Countries: 0. Publications: 0.
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression
ClinicalTrials.gov study NCT03887741. IPD Sharing: NO. Countries: 1. Publications: 0.
Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.
ClinicalTrials.gov study NCT04070885. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Predicting Disease Progression in Atrial Fibrillation: A Multiparametric Approach for Prognostic Marker Identification and Personalized Patient Management
ClinicalTrials.gov study NCT06647914. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dietary Acid Reduction and Progression of Chronic Kidney Disease
ClinicalTrials.gov study NCT06046924. IPD Sharing: YES. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.